Description of Invention:
DHHS announces the availability of select gp100 cancer antigens for licensing. These antigens are composed of a class that fall under the following definition:
gp100 P Core Peptide(s), meaning any gp100 peptide of nine (9) to fifteen (15) amino acids in length which is capable of eliciting an HLA-A2.1-restricted cytotoxic T cell response, and which comprises the formula X1X2X3PGPX5TX4, where X1 is any naturally occurring amino acid, X2 is any hydrophobic aliphatic amino acid; X3 is any naturally occurring amino acid; X4 is any hydrophobic aliphatic amino acid, and X5 is the amino acid V, C, I, L, or M.
gp100 is a tumor specific melanoma antigen. gp100 has been shown to be successful in stimulating the immune response to melanoma in humans.
Inventors:
Yutaka Kawakami (NCI) Steven A. Rosenberg (NCI)
Patent Status:
U.S. Patent 5,844,075 issued 01 Dec 1998 (DHHS Reference No. E-057-1994/2-US-01)
U.S. Patent 6,537,560 issued 25 Mar 2003 (DHHS Reference No. E-057-1994/2-US-02)
Related Technologies:
U.S. Patent 5,874,560 issued 23 Feb 1999 (DHHS Reference No. E-057-1994/0-US-01)
U.S. Patent 5,994,523 issued 30 Nov 1999 (DHHS Reference No. E-057-1994/0-US-02)
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
